Dermatology Review,
Год журнала:
2024,
Номер
111(1), С. 1 - 19
Опубликована: Янв. 1, 2024
AMA
Matusiak
Ł,
Walecka
I,
Reich
A,
et
al.
Polish
guidelines
for
the
diagnosis
and
treatment
of
hidradenitis
suppurativa.
Dermatology
Review/Przegląd
Dermatologiczny.
2024;111(1):1-19.
doi:10.5114/dr.2024.140820.
APA
Matusiak,
Ł.,
Walecka,
I.,
Reich,
A.,
Bieniek,
Krasowska,
D.,
&
Barańska-Rybak,
W.
(2024).
Dermatologiczny,
111(1),
1-19.
https://doi.org/10.5114/dr.2024.140820
Chicago
Łukasz,
Irena
Adam
Andrzej
Dorota
Wioletta
Beata
Bergler-Czop
2024.
"Polish
suppurativa".
Dermatologiczny
111
(1):
Harvard
W.,
Bergler-Czop,
B.,
Lesiak,
Narbutt,
J.,
Owczarczyk-Saczonek,
Owczarek,
Szepietowski,
J.
pp.1-19.
MLA
Łukasz
suppurativa."
vol.
111,
no.
1,
2024,
pp.
Vancouver
Bieniek
Krasowska
D,
Barańska-Rybak
W
Expert Review of Clinical Immunology,
Год журнала:
2023,
Номер
20(5), С. 525 - 545
Опубликована: Дек. 22, 2023
Introduction
Hidradenitis
suppurativa
(HS)
is
an
autoinflammatory
skin
disease
with
a
high
unmet
need
for
effective
medical
management.
Clinically,
it
characterized
by
inflammatory
nodules
that
may
progress
into
abscesses,
draining
tunnels
and
extensive
scarring,
mainly
affecting
apocrine
gland-bearing
areas.
Journal of the European Academy of Dermatology and Venereology,
Год журнала:
2024,
Номер
unknown
Опубликована: Дек. 19, 2024
Abstract
Introduction
This
second
part
of
the
S2k
guidelines
is
an
update
2015
S1
European
guidelines.
Objective
These
aim
to
provide
accepted
decision
aid
for
selection,
implementation
and
assessment
appropriate
sufficient
therapy
patients
with
hidradenitis
suppurativa/acne
inversa
(HS).
Methods
The
chapters
have
been
selected
after
a
Delphi
procedure
among
experts/authors.
Certain
passages
adopted
without
changes
from
previous
version.
Potential
treatment
complications
are
not
included,
being
beyond
scope
these
Results
Since
publication,
validation
new
therapeutic
approaches
has
almost
completely
overhauled
knowledge
in
field
HS
treatment.
Inflammatory
nodules/abscesses/draining
tunnels
primary
lesions,
which
enable
classification
disease
severity
by
validated
tools.
In
relation
degree
detectable
inflammation,
classified
into
inflammatory
predominantly
non‐inflammatory
forms.
While
intensity
form
can
be
subdivided
IHS4
mild,
moderate
severe
treated
medication
accordingly,
on
surgical
based
Hurley
stage
affected
localization.
effectiveness
oral
tetracyclines
as
alternative
combination
clindamycin/rifampicin
should
noted.
duration
systemic
antibiotic
shortened
5‐day
intravenous
clindamycin
Adalimumab,
secukinumab
bimekizumab
subcutaneous
administration
approved
EMA
moderate‐to‐severe
HS.
Various
procedures
available
disease.
medical
reduce
inflammation
remove
irreversible
tissue
damage
currently
considered
holistic
approach.
Conclusions
Suitable
options
while
considering
algorithm
according
standardized
criteria
aimed
at
ensuring
proper
therapy.
British Journal of Dermatology,
Год журнала:
2025,
Номер
192(Supplement_1), С. i15 - i21
Опубликована: Фев. 1, 2025
Abstract
The
therapeutic
pipeline
for
moderate-to-severe
hidradenitis
suppurativa
(HS)
is
robust.
Successes
and
lessons
learned
have
led
to
improvements
in
trial
designs
aimed
at
avoiding
prior
pitfalls,
as
well
high
placebo
response
HS,
which
remains
a
fundamental
threat
drug
development.
Herein,
we
review
the
evolutions
HS
trials
over
last
20
years
with
respect
overall
design,
sample
size,
diversity
enrolment,
inclusion
criteria,
concomitant
medications,
rescue
therapy,
endpoints
statistical
design
analysis
plans.
Areas
of
focus
that
merit
future
consideration
are
also
highlighted.
Annals of the Rheumatic Diseases,
Год журнала:
2025,
Номер
unknown
Опубликована: Фев. 1, 2025
This
systematic
literature
review
(SLR)
on
efficacy
outcomes
was
performed
to
inform
the
2024
update
of
expert
consensus
statement
treatment
immune-mediated
inflammatory
diseases
(IMIDs)
with
Janus
kinase
inhibitors
(JAKi).
An
2019
SLR
in
MEDLINE,
Embase,
and
Cochrane
Library.
For
efficacy,
randomised,
placebo
(PLC)-
or
active-controlled
trials
all
JAKi
investigated
IMIDs,
as
well
cohort
claims
data
for
conditions
where
such
studies
were
not
available,
included.
In
total,
10,556
records
screened,
182
articles
included
final
analysis,
investigating
21
51
IMIDs.
Forty-three
phase
2
59
3
9
strategic
72
pilot
case
series
considered.
demonstrated
both
PLC-controlled
head-to-head
comparisons
against
active
comparators,
93
102
randomised
controlled
(RCTs)
meeting
their
primary
endpoints.
Since
2019,
8
have
received
approval
by
Federal
Drug
Agency
European
Medicine
11
IMIDs;
these,
2,
no
approved
disease-modifying
antirheumatic
drug
(DMARD)
therapy
had
previously
been
available.
are
effective
treating
various
compounds
recently
approved.
The
impact
(JAK)
selectivity
distinct
JAK-STAT
pathways
needs
further
investigation,
few
also
available
sustained
disease
control
upon
tapering
withdrawal
optimal
placement
international
algorithms.
Annals of Dermatology,
Год журнала:
2024,
Номер
36(4), С. 197 - 197
Опубликована: Янв. 1, 2024
Vitiligo
is
a
chronic
autoimmune
disease
that
causes
depigmented
patches
on
the
skin.
It
affects
0.5%-2.0%
of
global
population.
goes
beyond
physical
appearance,
often
leading
to
stigmatization,
low
self-esteem,
and
depression,
burdening
patients
with
psychosocial
challenges.
The
pathogenesis
vitiligo
involves
loss
melanocytes
due
autoreactive
CD8+
T
cells,
triggered
by
environmental
stressors
exacerbated
cellular
vulnerabilities
immune
responses.
release
danger
signals
pro-inflammatory
factors
initiates
an
cascade
perpetuating
melanocyte
destruction,
mainly
driven
interferon-γ
C-X-C
motif
chemokine
ligand
9/10-chemokine
receptor
3
axis.
Long-lasting
tissue-resident
memory
cells
(Trms)
cytokines
contribute
lesion
persistence.
Current
treatments
focus
topical
steroids
tacrolimus,
systemic
steroids,
phototherapies,
but
their
efficacy
remains
suboptimal,
necessitating
development
new
therapeutic
options.
Building
recent
advancements
in
understanding
immunological
mechanisms
pathogenesis,
initiation
Food
Drug
Administration
approval
ruxolitinib,
various
potential
treatment
options
such
as
JAK
inhibitors,
cytokine
blockers,
Trm
or
regulatory
cell
targeting
agents
are
being
clinically
researched
anticipated
for
based
both
preclinical
clinical
data.
This
review
aims
categorize
summarize
diverse
investigational
drugs
currently
undergoing
trials
vitiligo.
By
examining
outcomes,
it
this
will
bring
hope
dermatologists
regarding
vitiligo,
condition
has
historically
posed
challenges
transform
into
realm
possibilities.
The Journal of Dermatology,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 15, 2025
Itch
is
a
prominent
symptom
in
many
cutaneous
disorders,
including
atopic
dermatitis
(AD),
prurigo
nodularis,
and
psoriasis.
also
common
but
overlooked
concern
patients
with
hidradenitis
suppurativa
(HS).
Currently,
the
mechanisms
underlying
itch
HS
remain
unclear.
To
gain
better
understanding,
we
reviewed
literature
on
pruritus
other
itch-predominant
AD,
In
HS,
psoriasis,
found
that
often
co-localized
pain
occurred
more
frequently
at
night.
Furthermore,
was
to
negatively
affect
sleep
increase
risk
for
comorbid
psychiatric
disorders
AD.
However,
HS-,
psoriasis-,
AD-related
differ
temporality.
AD
described
as
chronic,
while
psoriasis
episodic.
HS-associated
likely
multifactorial,
several
have
been
proposed
peripheral
sensitization,
central
neuroinflammation.
Prior
studies
highlight
enhanced
IgE
production
dense
infiltration
of
mast
cells,
along
variety
cytokines
chemokines.
alterations
skin
microbiome
may
contribute
HS.
date,
few
therapies
studied
treat
Given
efficacy
biologics
small
molecules
treating
similar
agents
be
explored
future
studies.
Alternative
target
neurological
contributions
include
anticonvulsants,
cannabinoids,
nonpharmacological
treatments.
conclusion,
pathomechanisms
fully
elucidated.
can
draw
lessons
from
pruritic
begin
addressing
it
identify
important
questions
study.
